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1. INTRODUCTION
Several major diseases, such as cancer and cardiovascular
abnormalities, may be linked to pathological deposition of
minerals or organic compounds in various tissues.1−3 Thus, the
detection of such minerals or compounds and understanding
the physicochemical processes associated with their formation
are essential.
dx.doi.org/10.1021/cr200068d | Chem. Rev. 2012, 112, 5092−5120
As underlined by Schmidt et al.,4 in Europe and the U.S.,
breast cancer will occur in 1 in 10 women. If clustered
calcifications5 are one of the mammographic signs of early
breast cancer, their chemical nature must be determined. More
precisely, calcium phosphates (CaPs) are frequently associated
with malignancy, but calcium oxalates are present in benign
lesions.6−10
From a medical viewpoint, pathological calcifications11,12
refer to at least three very different families of biominerals:
concretions, metastatic calcifications and dystrophic calcifica-
tions. Concretions are found in hollow organs or ducts of the
body. For example, kidney stones13−16 are solid concretions of
dissolved minerals in urine found in the kidney. In contrast,
metastatic and dystrophic calcifications, which can be
considered ectopic calcifications,17 are defined as unexpected
biomineralization18,19 occurring in soft tissues.20 In the absence
of a systemic mineral imbalance, dystrophic calcification is often
associated with tissue alteration or necrosis.21 In contrast,
metastatic calcifications resulting from mineral imbalance are
more systemic and affect various tissues (e.g., vessels, lungs,
kidneys). A fourth family can be considered physiological
calcification (bone), which becomes pathological with diseases
such as arthrosis or osteoporosis.
In all cases, complex interactions between cells and crystals
are involved, as illustrated in Figure 1.
Figure 1 shows some of the biochemical mechanisms
occurring between crystals and cells in cartilage (details in ref
22). Extracellular inorganic pyrophosphate (ePPi) concen-
tration is controlled by 3 ectoenzymes: membrane glycoprotein,
multipass transmembrane transporter, and tissue-nonspecific
alkaline phosphatases. With decreased ePPi concentration,
extracellular inorganic phosphate (ePi) can form basic CaP
(BCP) crystals within matrix vesicles. Through this mechanism,
ePPi and inorganic phosphate (Pi) imbalance determines the
calcium crystal type.
Both calcium pyrophosphate dihydrate (CPPD) and BCP
crystals, directly activate the articular chondrocytes responsible
for a real “crystal-induced stress”, similar to stresses with the
previously well-known and well-described mechanical, or
oxidative stress, or biochemical stresses in osteoarthritic
cartilage. This cell activation may ultimately lead to significant
changes in articular chondrocyte phenotype.
Different aspects of such calcifications must be taken into
account to establish a significant relationship with the disease.
These include chemical diversity, morphologic features at the
mesoscopic and macroscopic scale, location in the organ,
presence of trace elements (which could be catalytic agents),
presence of molecular groups, such as carbonate groups in
apatites and, finally, proteins.
In terms of chemical diversity, all pathological calcifications
mainly contain CaPs. However, secreting organs such as biliary
tract and kidneys show a great chemical diversity of crystalline
compounds. In fact, more than 100 chemical compounds have
been identified in the kidney and include calcium and
magnesium salts (phosphates, carbonates, sulfates, oxalates)
or organic compounds (purines, aminoacids, lipids, proteins,
and drugs).
The morphologic features of the calcification must be
considered,23,24 especially for concretions. For example, with
kidney concretions, whewellite (calcium oxalate monohydrate)
stones, depending on their morphologic features at both
macroscopic and mesoscopic scales, can be associated with an
alimentation disorder25 or a genetic abnormality, namely
primary hyperoxaluria.26 From a physicochemical point of
view, we used the terms “nanocrystals” and “crystallites” to
define the structural hierarchy of these mineral concrements.
Crystallites (measuring typically some tens of micrometres) are
made of a collection of nanocrystals (measuring typically some
hundreds of nanometres).27 Of note, we have underlined a
close relationship between stone morphologic features and
crystallite organization at the mesoscopic level and the
effectiveness of extracorporeal shockwave lithotripsy.19
The location of the ectopic calcification in the organ is of
prime importance in disease. For example, vascular calcifica-
tions may occur at different areas of the vessel wall, including
the intima in atherosclerosis and the media in Mönckeberg’s
sclerosis.28
We have also to consider the interface between the
calcification and the biological environment. Obviously, this
interface plays a significant role in the nucleation and crystal
growth of the calcification. As pointed out by C. Rey et al.,29 a
special characteristic of biological and synthetic nanocrystalline
apatites is the existence of a structured surface hydrated layer
which is involved in the protein/inorganic recognition and
interaction30−32 as in the formation of dental structures.33
Regarding concretions,34 it is at this interface also that the
organism will send different compounds to prevent the growth
or to inhibit the fixation of the mineral.
Finally, special attention must be paid to the presence of
trace elements and molecular groups at the surface or inside the
mineral.35,36 These trace elements have been the subject of
numerous studies in chemistry37 or medicine38−41 to elucidate
their role regarding the crystal formation kinetics42,43 or the
morphologic features of the mineral.44 A recent study
highlighted that Zn45 may have an inhibitory effect on calcium
oxalate (CaOx) stone formation, whereas Fe and Cu could
promote CaOx stone formation.46,47 The carbonate level of
biological apatites is also an interesting feature. A close
relationship was observed between the presence of bacterial
imprints,48 indicative of past or current urinary tract infection,
and the presence of amorphous carbonated CaP (or that of
whitlockite) and a high ratio of CO3
2− to PO4
3− of apatite.49
Figure 1. Simplified schematic illustrating the complex interaction
between crystal (calcium pyrophosphate dihydrate [CPPD] or basic
CaPs [BCP]) and cells. PPi, inorganic pyrophosphate; Pi, inorganic
phosphate.
Note that such bacterial imprints are not present in infectious
struvite kidney stones.50
The presence of small amounts of other mineral ions, such as
Na+, K+, F−, OH−, and CO3
2−, influences the reactivity and
stability of biological apatites, inducing subtle changes in their
microstructural features.51,52 More precisely, high resolution
electronic microscopy revealed that the incorporation of Zn
ions in the crystal lattice of carbonate-containing apatites
reduced the number of structural defects.53
In the hospital, noninvasive methods are preferentially
selected for the analysis of deposits. Thus, calcifications are
detected by radiography,54 with considerable effort made to
improve this technique. Contrast agents55 can be used to
artificially alter X-ray attenuation locally (e.g., blood vessels in
an organ), and synchrotron radiation (SR) has replaced the
conventional X-ray source.56,57 In fact, compared with conven-
tional generators, the use of phase-sensitive techniques reduced
the delivered dose and improved the image contrast.58 With
invasive techniques, calcifications in biopsies and extracted
samples can be characterized by optical microscopy after
adequate coloration to allow for visualization of submillimeter
calcifications.59 Of note, staining alone is not sufficient to
confirm the presence of calcification.60 Such approach is the
basis of the work of anatomopathologists. Identification can be
completed by other techniques routinely used in some cases:
Fourier transform infrared (FTIR)61 and Raman spectrosco-
py,62 as well as classical X-ray diffraction (XRD). Hospital
research takes advantage of other sophisticated techniques.
This review focuses on the structural characterization of
pathological calcifications mainly through SR63 and neutron-
related techniques64,65 to complete the characterization
performed in the hospital. We reveal the possibilities with use
of these large-scale instruments for determining the size and
morphologic features of the nanocrystals contained in these
biological entities and for other aspects that are crucial from a
medical66,67 and chemical viewpoint: the presence of trace
elements, the molecular groups at the surface and the possibility
of studying the interface between cells and mineral. Recent
reviews68,69 have underlined the advantages and the limitations
of different SR-related techniques used now as X-ray microp-
robes.70,71 Also, a set of excellent reviews have focused on
different SR techniques, from FTIR spectrometry72,73 to
XRD,74−76 X-ray fluorescence (XRF),77,78 and X-ray absorption
spectroscopy (XAS).79 Thus, we provide only a brief
description of the physics associated with these techniques
before a review of different medical or physico-chemistry
research works. We discuss the following points in terms of
hospital care (i.e., FTIR spectrometry), with reference to
advantages of the techniques implemented for large-scale
instruments from a medical viewpoint: (1) the determination
of the chemical composition and the presence of molecular
groups of medical importance, such carbonate by FTIR
spectrometry, (2) the structure of the elementary crystals and
its interface by diffraction techniques and XAS, and (3) the
nature of trace elements present and a proposition to classify
them by XRF.80
Of note, the ultimate goal is to use techniques usually
dedicated to fundamental physics and those related to large-
scale facilities for characterizing pathological calcifications at the
subcellular scale to (1) establish a possible link between the
chemical characteristics of the calcification and the abnormality,
(2) allow for an early diagnosis, and (3) revisit results provided
early by more classical techniques.
We would like to describe some basic aspects of pathological
calcifications from a medical and chemical viewpoint. This brief
description (additional information can be obtained in excellent
reviews dedicated to biomineralization processes81) is a
prerequisite to appreciate the complexity of such objects and
the need for intimate collaboration between physicist, chemist,
and clinician scientific communities.
We will review some physicochemical aspects82 related to
solubility, nucleation and crystal growth, especially of calcium
salts encountered in pathological calcifications, and the role of
proteins in these processes.
2. MEDICAL ASPECTS REGARDING PATHOLOGICAL
CALCIFICATIONS
First, we show the different levels of complexity of pathological
calcifications. Such biological entities are present almost
everywhere in the human body. Their origin is complex and
can be induced by different kinds of abnormalities (metabolic
syndrome, genetic, infection). Also, such pathological calcifica-
tions may have a hierarchical structural organization, which can
be related to the history of the patient.
2.1. Generalities on Pathological Calcifications
Pathological calcifications may occur in various parts of the
body, namely, joints,83 brain,84−88 breast,89−92 cartilage,93−95
cardiac valves,96,97 middle ear,98 gallbladder,99 gastric system,100
heart,101,102 intestine,103 kidney,104−107 larynx,108,109
liver,110−112 lungs,113−115 pancreas,116,117 prostate,118,119 sali-
va,120 tendons,121 testicles,122,123 tooth,124 thyroid,125−127 and
artery or vessels128−134 affecting adults, as well as fetuses and
newborns.135,136 Calcifications of placenta have also been
observed.137 Calcifications of medical devices made of polyur-
ethane, silicones, and hydrogels have been widely reported.
These devices include bioprosthetic heart valves138−141
cerebrospinal fluid shunts, mammary implants,142 contraceptive
intrauterine devices,143 stents,144,145 and intraocular lens.146−148
We highlight different specific structural aspects of
pathological calcification by scanning electron microscopy
(SEM) observations related to major medical aspects (Figure
2).
For example, physiological calcifications are organized on
different spatial scales. Pathological calcifications can be
organized as well (Figure 2), and such spatial organization of
the chemical phases is linked to the case history (an example is
given later). For a Brushite kidney stone, the radial organization
is clearly visible. Moreover, at the center of the kidney stone,
apatite can be present (Figure 2B).
Figure 2C and D shows whewellite kidney stones. Crystallites
of kidney stones in Figure 2C are linked to primary
hyperoxaluria type 1, a rare inherited disease leading to
recurrent nephrolithiasis, nephrocalcinosis, systemic oxalosis,
and renal failure, ultimately requiring combined kidney and
liver transplantation,149.150 At the opposite, crystallites of
kidney stones shown in Figure 2D are commonly observed
for idiopathic type of whewellite stones related to a disordered
alimentation. From these observations, we propose that a
morphologic examination be performed before compositional
analysis by means of X-ray diffraction or infrared spectroscopy,
because this direct SEM examination constitutes a simple,
rapid, and cheap tool that might point to the early diagnosis of
primary hyperoxaluria type 1.
Figure 2E and F shows calcifications at the surface of calcified
cardiac valves. Such observations demonstrate that the
morphologic features of such calcifications can be quite
different. Bundles of faceted microrods are shown in Figure
2E, and round-shaped or sphere-like, flat structures adherent to
the leaflet surface are observed in Figure 2F: the first species
seems to be inserted into the leaflet surface and such
configuration can give some information regarding the
interaction between the calcification and the tissues.
2.2. Origins
Figure 3 illustrates the diversity of origin of calcifications by
SEM.
Hyperoxaluria in urine leads to the formation of whewellite
kidney stones, whereas hypercalciuria is the origin of weddelite
(calcium oxalate dihydrate) stones (Figure 3B). Infection is also
a cause of kidney stones, and Figure 3C shows some
fingerprints at the surface of spherical apatite crystallites,
whereas the calcification seems to be present around the
bacteria. Aging can lead to calcification; Figure 3E shows the
presence of calcium pyrophosphate crystals at the surface of the
cartilage. In Figure 3D, we can observe the presence of 2,8-
dihydroxyadenine (2,8-DHA) crystals the formation of which is
due to adenine phosphoribosyltransferase (APRT) deficiency
related to a genetic disease. APRT deficiency is a rare, but
potentially severe autosomal-recessive inborn error of purine
metabolism that is largely underdiagnosed.151
Several works have underlined that the cell environment may
change its functioning. Recently, Giachelli152 investigated the
role of phosphate level in transforming the vascular phenotype
of cultured human aortic smooth muscle cells to an osteogenic
phenotype, to create a predisposition for calcification. Sun et
al.153 demonstrated that BCP crystals stimulate the uptake or
endocytosis of DNA plasmid and that this is accomplished
mainly by rendering the cells more permeable. Also, Hsu et
al.154 showed that bicarbonate buffer could provide a dynamic
and rapid transitional increase in pH of extracellular fluids,
thereby creating a favorable condition for the initiation of
vesicle-mediated calcification under pathological conditions.
Recent observations155 have suggested that ectopic calcification,
like bone biomineralization, is an actively regulated process.
Breast tissue is heterogeneous, associating connective and
glandular structures, which grow and change cyclically under
hormonal regulation. Hormones are thought to be the main
determinant factor of the major benign and malignant
abnormalities encountered in the breast.156,157
Several mechanisms are involved in calcification. For
example, with prostatic calculi, Klimas et al.158 highlighted
two related mechanisms: calcification of corpora amylacea and
simple precipitation of prostatic secretion. The genesis of
pathological calcifications of the basal ganglia has been linked to
more than 30 medical conditions, including infectious,
metabolic, and genetic syndromes.159,160
In many tissues of the body, inflammation often induces
small calcium deposits.161 For example, microcalcifications are
less commonly associated with prostate cancer than with
benign prostatic ducts alterations and aging.162 In contrast,
intratesticular microlithiasis is highly associated with testicular
cancer.163 Also, some abnormalities such as cystinosis, a
metabolic disease, are characterized by accumulated cystine in
different organs and tissues, thus leading to potentially severe
organ malfunctioning.164
Finally, the possible involvement of nanobacteria could be
considered in the mechanism for pathogenic intra- and
extracellular calcification and concretion formation.165−170
Note that recent results definitively ruled out the existence of
Figure 2. Spatial organization of pathological calcifications. (A) A
kidney stone of brushite displays a radial distribution of acicular
crystallites with a center of spherical apatites (B). Crystallites of
whewhelite have various morphologic features and various agglomer-
ation modes. Whewellite crystallites related to a genetic disease (C)
have a morphologic and agglomeration type different from whewellite
kidney stones related to dietary disorders. Calcifications on cardiac
valve (E, F) may have different morphologic features.
Figure 3. Examples of calcification: kidney stones related to
hyperoxaluria (A) and hypercalciuria (B), presence of bacterial
imprints with infection (C), presence of dihydroxyadenine crystals
with genetic disease (D), calcification on cartilage due to aging (E),
cholesterol calcifications present in the biliary system (F) are also
associated with alimentation disorder.
‘‘nanobacteria’’ as living organisms and pointed out the
paradoxical role of fetuin.171
2.3. Concretion on Ectopic Calcification
Pathological calcification may have a complex organization
from the history of the abnormality. For example, athero-
sclerosis involves early deposition of cholesterol, cholesterol
esters, and related lipid compounds (and their oxidation
products) on the inside walls of arteries.172 In advanced stages,
atherosclerotic plaques may become calcified by the codepo-
sition of CaP. Therefore, CaP nucleation and crystal growth on
cholesterol and cholestanol surfaces must be studied from a
supersaturated simulated body fluid.173
With concretion, the existence of intracrystalline proteins and
amino acids in whewellite was demonstrated by X-ray
synchrotron diffraction studies. As found by Fleming et al.174
their presence have implications for the destruction of CaOx
crystals formed in the urinary tract and the prevention of
kidney stones (KS).
In the kidney, ectopic calcification, named Randall’s plaque
(RP),175 is a support for the nucleation and growth of
concretion (i.e., kidney stone; Figure 4A).176 Recently,
endoscopy revealed RP commonly present on papilla of
calcium oxalate stone formers.177 Evan et al.,178 taking
advantage of percutaneous nephrolithotomy procedures in 15
recurrent calcium oxalate stone formers, showed that interstitial
apatite plaque particles first appear in the basement membranes
of the thin loops of Henle.́ In addition, the authors showed that
stone formation activity is proportional to the surface of
papillae covered by RP179 and that the mean fractional plaque
coverage is higher in calcium oxalate stone formers with the
highest urinary calcium concentration.180 This situation is the
subject of numerous studies investigating the interface between
the concretion and the ectopic calcification as well as
determining the nature of proteins present to prevent the
formation of RP.181
SEM at the mesoscopic scale can reveal structural
information. As previously described, Figure 4A shows RP at
the surface of the calcium oxalate kidney stone (CaOx KS in
Figure 4A). These CaP deposits of carbonated apatite likely
from both interstitium and neighboring collecting ducts may
cover the surface of the papillary epithelium (RP in Figure 4B).
SEM at the mesoscopic scale (Figure 4C) shows the plaque
appearing as a complex structure containing calcified tubules
and vessels (white arrows) and tubules filled by carbonated
apatite plugs (black arrows). The smooth part of the plaque
(white arrowhead) suggests that a layer of carbonated apatite,
probably from neighboring tubules, covers the papilla
epithelium. Finally, SEM allows for a detailed description of
the interface area between an RP and a whewellite stone
(Figure 4D). This technique shows randomly distributed CaOx
monohydrate crystals (right) trapped in the carbonated apatite
of RP (left). Such structural description can reveal the
biochemical mechanism responsible for the development of
the kidney stone from the RP. The presence of RP made of
carbonated apatite spherules (white arrow in Figure 4D)
appears joined by an unstructured material, identified as
proteins using infrared spectroscopy; this biomaterial made of
a mineral nanocrystals and protein acts as a glue to fix CaOx
crystallites (black arrows in Figure 4D).
3. PATHOLOGICAL CALCIFICATIONS AND
PHYSICOCHEMISTRY
Lowenstam182,183 has defined two modes of biomineraliza-
tion:184,185 biologically induced and biologically controlled
biomineralization. In the first case, chemical variations as a
result of the metabolic activity of microorganisms lead to
precipitation in the external environment of the bacteria.
Biominerals are thus not directly associated with cellular
structures, whereas a specific nucleation intracellularly or on the
cell wall is observed during the biologically controlled process.
The study of biomineralizations is an active interdisciplinary
field.186 Biomineralization covers the full spectrum of issues
devoted to the study of minerals produced by living
organisms.187 From a fundamental viewpoint, crystallization
may be induced in metastable supersaturated biological or
synthetic solutions by spontaneous nucleation when a certain
degree of supersaturation is reached (homogeneous nucleation)
or by seed crystals or polymeric substances (heterogeneous
nucleation). Although seed crystals of the growing substance
are usually the most effective, the crystallization may also take
place on the surface of other materials/substances which offer a
good crystal lattice or surface structure to match the main
crystalline plane of the substance being precipitated.
In biological mineralization, epitaxial crystal growth is of
prime importance for understanding the formation of teeth and
bone, as well as pathological processes such as urinary calculi.
The formation of pathological calcifications involves complex
mechanisms that, in most cases, are still to be elucidated. For
example, stones form in a complex environment with constant
formation of urine at a variable flow rate, pH and composition.
Although supersaturation must be reached for the precipitating
phase, it alone does not predict stone formation. Other factors
such as the presence of inhibitors of crystal growth, the matrix,
sites of formation and retention, and accretion of smaller
entities, may be important.
The study of pathological calcifications is thus related to
some fundamental physical−chemical aspects, such as the
solubility of mineral phases, nucleation and crystal growth and/
or aggregation processes and interfacial phenomena (adsorp-
tion and surface reactions based on interaction between mineral
and proteins or ions as crystallization promoters or inhibitors,
Figure 4. (A) Randall’s plaque (RP) made of apatite on top of a
kidney stone of whewellite (CaOx KS). (B) RP at the surface of the
papilla. SEM micrographs: (C) RP appears as a complex structure
containing calcified tubules; (D) of interface area between RP and a
whewellite stone.
etc.). We discuss these aspects, especially in terms of biorelated
CaP formation.
3.1. Hierarchical Structure
Biological calcified entities show several levels of organiza-
tion188,189 resulting from an agglomeration of crystallites (their
dimension is typically at the micrometer level and can be
observed by SEM), and each crystallite appears to be made of
nanocrystals (their dimension is typically of some hundreds of
nanometers and can be determined by X-ray or neutron
diffraction).
Figure 5 shows that such hierarchical structure can be far
more complex. SEM reveals the complexity of a kidney stone
structure mainly made of brushite from the macroscopic to
mesoscopic scale. Brushite crystallites may have particular
structures (Figures 5B, C, D). Figures 5E and F show neutron
and X-ray scattering diagrams of a kidney stone. The presence
of nanocrystals of 150 nm size in kidney stone can be revealed
by fine analysis of the diffraction diagram collected with
neutrons, whereas a simple observation by 2D X-ray scattering
reveals rings and dots, which underlines that quite large crystals
are also present in the kidney stone.
3.2. Great Chemical Diversity
Different chemical phases can be identified inside or at the
surface of microcalcifications. As shown in Table 1, if calcium is
involved in numerous phases (calcification comes from calx:
calcium monoxide CaO), organic compounds such as
Figure 5. Characterization of a kidney stone mainly composed of
brushite: (A) SEM micrograph of kidney stone at the macroscopic
scale: the dimension ranges from 1 mm to 1 or 2 cm. (B) SEM
micrograph of an acicular crystallite. (C, D) SEM micrographs
showing details of the acicular crystallites. (E) Neutrons diffraction
diagram corresponding to 150 nm size crystals. (F) 2-D X-ray
scattering diagram of the same time rings, with dots illustrating that
large and small crystals are present in the kidney stone.
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cholesterol or uric acid can also be the main constituent.
Particularly in kidney, amino acids such as cystine can be found
because of its low solubility.
Such biological entities may also have a drug origin.190 Drug-
induced renal calculi represent 1% to 2% of all renal calculi,
including two categories: those resulting from the urinary
crystallization of a highly excreted, poorly soluble drug or
metabolite and those due to the metabolic effects of a drug:
Indinavir or atazanavir used in HIV-infected patients,
sulfonamides, especially sulfadiazine, and triamterene are the
most frequently involved. The name and the chemical formula
of compounds found in pathological calcifications are reported
in Table 1.
Table 1 shows that CaP apatite is present in numerous
pathological calcifications, which is consistent with the content
of Ca in the human body (about 1 kg for a 72-kg body). From a
chemical viewpoint, the specificity of calcium results from its
coordination geometry often being irregular and strongly
influenced by the second coordination sphere.223
Apatite is general ly descr ibed by the formula
Me10(XO4)6(Y)2 with Me representing a metal (Ca
2+, Sr2+,
Mg2+, Pb2+, Na+, K+, Eu3+, ..., a vacancy), XO4 representing an
anion (PO4
3−, SO4
2−, SiO4
4−, CO3
2−, HPO4
2−, ...), Y
representing an anion (OH−, Cl−, F−, CO3
2−, S2−, O2
2−, ... or
a vacancy). For carbonated apatite for example:
Ca10−x+u□x−u(PO4)6−x(CO3)x(OH)2−x+2u with □ correspond-
ing to vacancy, x ≤ 2 and u ≤ x/2.224 The apatite structure was
first determined on fluorapatite crystals (Ca5(PO4)3F) by
Naray-Szabo (1930) and was confirmed to adopt P63/m
symmetry.225
More precisely, we recall that hydroxyapatite (HAP,
Ca5(PO4)3(OH)) can be described as an hexagonal stacking
of PO4
3− groups with two kinds of tunnels parallel to the c axis.
The first one coincides with the ternary axis of the structure
and is occupied by Ca2+, noted Ca (I) ions. The second one is
bounded by oxygen and other calcium ions, noted Ca (II) ions,
and is occupied by OH− ions. Ca (I) and Ca (II) are present in
a ratio of 2 to 3.226 The diameter of such tunnels (3 Ǻ) gives
apatites properties of an ion exchanger but only at high
temperatures, and they can also act as a host to small molecules
and to different cations.
Biological apatites share different structural and chemical
properties. A first structural specificity emerges from the lack of
OH− as noticed by several studies based on infrared
spectroscopy and inelastic neutron scattering.227 Cho et al.
measured an OH− content of human cortical bone of about
20% of the amount expected in stoichiometric HAP.228 As
noted by Vallet-Regi and Gonzalez−Calbet, crystals are
nanometer in size, with an average length of 50 nm, 25 nm
in width, and thicknesses of just 2−5 nm, scattered in the
organic matrix.229 This small size is a crucial factor related to
the solubility of biological apatites as compared with geological
apatites. Also, alterations of these structural characteristics have
been considered a consequence of major abnormalities such as
osteoporosis.230 Biological apatite crystals displaying nanosize
dimensions are non stoichiometric apatites: the presence of
anionic (OH−) and cationic (Ca2+) vacancies has been
evidenced. The localization of these cationic vacancies has to
be determined.
3.3. Solubility of Mineral Phases Involved in Pathological
Calcifications
CaPs are involved in the calcium and phosphorus metabolism
in living organisms through dissolution/precipitation processes
related to controlled (normal) or uncontrolled (pathological)
local physicochemical conditions.
The solubility product is an important variable in
precipitation and dissolution processes of synthetic or bio-
logical mineral phases, such as carbonated apatites and other
biorelated CaPs.231 The formation of CaPs is highly sensitive to
the pH of the milieu because of the reactivity of
orthophosphate ions with H3O
+ according to the following
reactions:
+ ⇄ +− + −PO H O HPO H O43 3 42 2
+ ⇄ +− + −HPO H O H PO H O42 3 2 4 2
+ ⇄ +− +H PO H O H PO H O2 4 3 3 4 2
Considering the various equilibria and their corresponding
acidity constant, hydrogenphosphate ions are the main ionic
species in solution at 37 °C, with pH in the range 2.15 and
12.35 (2.15 < pH < 7.2 for H2PO4
− and 7.2 < pH < 12.35 for
HPO4
2−).232 CaPs, including both HPO4
2− and PO4
3−, occur in
mineralized tissues and various pathological calcifications.
Depending on the pH, composition and temperature of the
crystallization milieu (synthetic solutions or biological fluids),
several CaPs can precipitate (amorphous CaP, dicalcium
phosphate dihydrate (DCPD, brushite), octacalcium phosphate
pentahydrate (OCP), apatite, whitlockite; see Table 1).233
The solubility of CaPs is highly affected by the presence of
CO2 in the surrounding solution. Carbonate ions can substitute
for phosphate ions in the apatite lattice and even if the amount
of carbonate incorporated is relatively low (3−5%), its presence
influences the crystallinity, solubility and acid reactivity to a
significant extent. Solubility isotherms are shifted toward higher
Ca concentration (solubility increase) in solution at pH > 7,
probably because of the formation of CaHCO3
+ complex in
solution.234 At pH > 6.9, most CaP compounds are more
soluble than is calcite CaCO3. Under physiological conditions,
the presence of proteins and amino acids may favor CaP
dissolution, because they can form a complex with calcium. In
contrast, under certain conditions, the presence of H3O
+ ions
or of magnesium ions, for example, calcium ions from organic
complexes can be released because of the formation of more
stable magnesium complexes, thus favoring CaP precipitation.
3.4. Nucleation and Crystal Growth
Crystallization of a phase involves two steps: nucleation and
crystal growth. Primary nucleation can be classified as
homogeneous if it occurs within the solution or as
heterogeneous if it is induced by foreign particles/surfaces.155
According to the classical theory of precipitation, nucleation
represents an activation barrier to the spontaneous precip-
itation of a solid phase from a supersaturated solution
essentially related to the creation of interfacial energy.
Crystallization at surfaces (heterogeneous nucleation and
crystal growth) may be induced at supersaturations lower
than those required for spontaneous precipitation. Conse-
quently, in the presence of a foreign body or surface, the overall
free energy change associated with the formation of a critical
nucleus under heterogeneous conditions must be less than the
corresponding free energy change associated with homoge-
neous nucleation.235 However, the presence of adsorbed
molecules may change the interfacial energy in solution and
stabilize smaller nuclei than in solutions without adsorbate.
Epitaxy or oriented overgrowth is a special case of
heterogeneous nucleation whereby the growth of the nuclei
on the substrate follows a specific orientation.155,156 The
definite orientation in the crystalline overgrowth requires the
formation of a nucleus consisting of an immobile monolayer of
regular atomic patterns more or less fitting with the lattice
spacing of the crystalline substrate.236
Boistelle and Rinaudo237 showed in vitro the epitaxial growth
and phase transition between anhydrous and hydrated
polymorphs of uric acid, which can explain the formation and
evolution of these two compounds often found in urinary
calculi. Pak238 revealed the important role brushite can have in
the formation of calcium-containing renal stones. This
crystalline phase, identified in stone-forming urine and stones,
may undergo phase transformation to hydroxyapatite or cause
heterogeneous nucleation or epitaxial growth of calcium
oxalate.239
An interesting configuration is given by results from Omar et
al.240 indicating that although intact bacterial cells do not
provide suitable sites for heterogeneous nucleation in
crystallization processes, alterations to them caused by changes
in environmental conditions or processes that lead to autolysis
can result in such a process.
3.5. Important Markers of Biomineralization (CO3
2− and
HPO4
2−)
Apatitic CaPs can accommodate a wide range of ion
substitutions that can modify their physical-chemical and
biological properties. The most interesting possibilities are
observed with nanocrystalline apatites, which can be found in
many normal and pathological calcifications. The ability of both
biological and synthetic apatites to evolve and adapt to their
surrounding environment is related to their low crystallinity
and the extent of the hydrated surface layer containing the
labile nonapatitic species.161,241 Indeed, these compounds are
characterized by the existence of a hydrated layer of loosely
bound mineral ions (labile ions) on the crystal surface, which
can be easily exchanged in the environmental milieu. This layer
offers the possibility of trapping mineral ions and active
molecules. More generally, depending on their location in the
apatitic nanocrystals, foreign ions may be spontaneously
released by ion exchange involving calcium ions from the
surrounding fluids or by cell-mediated dissolution processes.242
Altered bulk properties (dissolution, dimensions, crystal
perfection) or surface properties (surface charge and energy,
surface defects, protein binding ability) can directly or
indirectly affect the behavior of cells.
Carbonate may play a key role in the crystallization kinetics
and the morphologic features of apatite crystals. For example,
Kapolos et al.243 suggested that carbonate incorporated in
apatite growing on seed crystals caused changes in their
morphologic features, favoring plate-like crystal formation.
However, the location of carbonate (CO3
2−) in the apatite
lattice has been controversial.244
Like carbonate ions, hydrogenphosphate ions (HPO4
2−)
appear to be an important marker of nanocrystalline apatites in
general and in bone mineral in particular; their concentration
has been shown to decrease upon aging/maturation. These ions
are present at high concentrations in newly formed apatite
crystals and in young bone and gradually diminish with time
(maturation).161,173 The presence and level of nonapatitic
hydrogenphosphate groups can determine the structure of
biorelated apatites and, most importantly, their function and
evolution.245
3.6. Synthetic Analogues of Biorelated Mineral Phases and
Crystallization Dynamic Modelization
Because of the complexity and heterogeneity of composition
and structure found in normal or pathological biological
calcified systems (Table 1), synthetic analogues of such
biominerals or biological fluids can be used to shed light on
the biomineral mode of formation and physicochemical
properties in vivo with in vitro model systems.246−250 The
synthetic analogues (standards) of the mineral phases involved
in pathological calcifications (nanocrystalline apatites, brushite,
OCP, and other biorelated calcium and magnesium phosphates,
calcium carbonate and calcium oxalate) can be prepared by
precipitation in aqueous solution. The availability of such
synthetic analogues allows to study the physical-chemical
properties and reactivity of these CaP phases separately or
together and to determine the effect of some promotors or
inhibitors of their formation and/or evolution in vitro. Then,
we can take advantage of this approach involving synthetic
analogues for screening various components with potential
therapeutic activity to prevent pathological calcifications.
Several studies have reported on the use of the (dual)
constant composition crystal growth technique (i.e., constant
temperature, ionic strength, supersaturation and ion concen-
tration in solution) for the dynamic study of stone-forming
minerals on the surface of other crystalline phases, cellular
material and immobilized macromolecules.251,252 Campbell and
co-workers253 showed significant differences in the inhibiting
and nucleating potential of whewellite crystallization on
hydroxyapatite (HAP) seeds in the presence of various
polyelectrolytes and proteins (poly-L-glutamic and poly-L-
aspartic acids, human serum albumin) introduced in solution
or adsorbed on seed surface. Lanzalaco et al.254 tested the effect
of urinary and matrix (kidney stones) macromolecular
components on whewellite crystallization using the same
technique. Recently, Tang et al.255 studied the crystallization
of whewellite in slightly acidic conditions: the authors showed
whewellite crystallization induced by the presence of brushite
crystals, readily formed in such pH conditions, and, once
formed, grew at the expense of brushite crystals (dissolution of
brushite crystals). These results reveal the crucial role brushite
may play in the initiation of whewellite crystal formation. In
addition, using the dual constant composition technique, Tang
et al.175 discussed the effect of uric acid and/or citrate ions in
the supersaturated solution on the aggregation state of formed
whewellite crystals.
The nucleation and crystal growth of CaCO3 polymorphs
can also be studied by a constant composition crystal growth
technique. Kanakis et al.256 reported a study of the
crystallization of vaterite CaCO3 on a bioprosthetic cardiovas-
cular valve with or without sodium alginate as anticalcification
treatment.
In addition, (dual) constant composition crystal growth can
also allow to study the dissolution kinetics of these mineral
phases.257
The use of synthetic urine-like calcium-rich or oxalate-rich
solution such as CaOx dihydrate258 for in vitro studies is of
great interest to better evaluate the components involved in
crystallization.
Finally, using atomic force microscopy configured with tips
modified with biologically relevant functional groups, Sheng et
al. compared the adhesion strengths of the morphologically
important faces of whewellite and weddelite.198 These
measurements seem to provide direct experimental evidence,
at the near molecular level, for poor adhesion at weddelite.259
3.7. Role of Proteins
The control of crystal nucleation and growth by proteins has
numerous consequences in understanding the basic mecha-
nisms of calcification. Besides the wealth of information about
the mineral and the matrix of normal or pathological calcified
tissues, many questions are still unanswered, especially
concerning the essential components involved in the initiation
of calcification (nucleation) and in the regulation of crystal
growth.
For example, urinary proteins, such as the Tamm-Horsfall
protein260−262 nephrocalcin,263−265 osteopontin266−268 and
human serum albumin269 are believed to have potential to
influence the crystallization of calcium oxalate. Rosenthal et
al.270 showed that osteopontin promotes CPPD crystal
formation in a well-characterized, chondrocyte-based model.
Osteopontin is present in articular cartilage affected by CPPD
deposition and may be an important factor in the development
of CPPD crystals in vivo. Other studies reported the
modulation of CaOx crystallization by osteopontin and
synthetic aspartic acid-rich peptides.271
Cheung et al.272 studied the specific inhibition of BCP and
calcium pyrophosphate crystal-induction of metalloproteinase
synthesis by phosphocitrate. The loss of activity of natural
calcification inhibitors changes tissue properties and promotes
pathological processes.273
Several attempts have been made to classify proteins as
promotors or inhibitors of biomineralization; most authors
have used model systems for such in vitro studies. However,
because of the variety of effects depending on their
concentration and/or conformation, classifying them is
difficult.274 Human serum albumin was found to nucleate
COM crystals when immobilized on hydroxyapatite.172 Addadi
et al.275 reported that the same macromolecule that acts as a
specific inhibitor of crystal growth when in solution, can
operate as a template for oriented crystal nucleation when
adsorbed on a solid substrate in the correct conformation.
These examples suggested that contradictory effects, probably
resulting from complex processes, may be due to the protein
source and purity, as well as the assay system. Moreover,
Mueller and Sikes276 suggested the existence of two general
classes of inhibitors, those affecting nucleation and those
affecting growth, because the mechanisms of nucleation and/or
transformation of CaP and growth differ.
One of the most interesting features is the dose-dependent
behavior noticed with several compounds. Combes et al.
showed that depending on the range of protein concentration
in solution, bovine serum albumin (BSA) can have a dual role
and act as a promotor or inhibitor of nucleation and growth of
octacalcium phosphate on type I collagen.277,278 Several years
before, Ebrahimpour et al.279 reported similar observations for
the influence of human serum albumin, adsorbed and in
solution, on CaOx nucleation and growth on hydroxyapatite.
The interpretation of these antagonist effects is based on two
physical-chemical phenomena related to adsorption: the effect
on nucleation rate and on crystal growth. With adsorption from
solution, the interfacial tension should decrease in the presence
of adsorbing molecules. Thus, the energy needed for
nucleation, which is related to surface creation, will decrease
if adsorbing molecules are present, and nucleation will be
easier: for a given supersaturation, the nucleation ability in a
solution containing adsorbing protein is greater, and multi-
plication of the nuclei will occur as a consequence of
adsorption, as compared with a system without adsorbing
protein. In most cases, the effect of protein adsorption on the
nucleation process can be more complex because adsorption
can occur on the substrate and the nuclei. Proteins may then
delay the crystal growth process because of their presence at the
solution−crystal interface, but this rarely results in the complete
inhibition of crystal growth, and crystals continue to grow at a
slower rate, possibly with modification of their morphologic
features. The slowing down of crystal growth is related to the
coverage of the crystal surface generally corresponding to a
Langmuir adsorption isotherm, which is related to the
concentration of the protein in solution.280,281 In addition to
these thermodynamic considerations, kinetic phenomena must
be considered. Because of their sizes, the proteins diffuse less
rapidly than do mineral ions. The progressive depletion of
adsorbing proteins occurring locally, related to nucleation and
mineral surface creation, may result in an increase exposition of
bare mineral surface and an increase of crystal growth, often
observed as a “burst” of crystal growth at a rate much higher
than that observed without proteins.
These are general phenomena that may occur with any
protein adsorbing on mineral crystals to a greater or lesser
extent. The borderline between activation and inhibition of the
growth rate may vary for each protein, and some might never
reach a concentration high enough to exhibit a global inhibition
effect. The overall precipitation rate (sum of new nucleus
formation and nucleus growth rate), which is the only
experimental factor that most authors consider can lead to a
variety of behaviors and may explain the contradictory results
concerning the effect of proteins on crystal growth.282−284
Nevertheless the local amount of adsorbing proteins appears to
be an important variable to consider before assessing inhibitor
or activator effects on calcification.
This review reveals the difficulties in classifying a protein as a
promotor, inhibitor or both of mineral precipitation depending
on the system used and the range of protein concentrations
studied. In dynamic systems, the problem is even more complex
because of the different rates of diffusion of proteins and
mineral ions and depletion of potential inhibitors that may
result when active nucleation is involved. Several variables are
important in this kind of in vitro study: protein source and
purity, assay system, ratio of solid to liquid used in vitro as
compared with the contact surface involved in vivo, and the
solution pH, because the protein−surface interaction is driven
by surface charge.285,286 However, we must remember that
determining whether a protein is a nucleator, inhibitor or both
of the crystalline phase (found in normal or pathological
calcification) precipitation in vitro does not indicate that it has
the same effect in vivo.
Regarding cations such as Fe, Sr, Se and Zn, which are
present in several essential biological metalloproteins, signifi-
cant investigations have been performed to understand the
mechanism of interaction of these trace elements with the
surface of apatite crystals. For example, Sheha et al. reported
that the mechanism of metals interacting with apatite depends
intimately on the experimental conditions (i.e., pH and the
nature of the Zn2+ species).287
4. CHEMICAL ANALYSIS BY FTIR SPECTROMETRY
FTIR spectroscopy is based on the study of molecular motion
interacting with a broadband infrared source. Of note, the
vibrational motions of individual chemical bonds for all
molecules lie in the wavelength range 2−20 μm corresponding
to the wavenumber 5000−500 cm−1. FTIR spectroscopy is a
vibrational spectroscopy reflecting molecular structure, so it is
also sensitive to molecular environment.288 This method is able
to determine the chemical composition of the sample of
interest but is limited in that only molecules that exhibit
vibrational modes sensitive to infrared photons are revealed.
With biological samples, the major advantages of FTIR
spectroscopy is that a limited number of main features exist in
the infrared spectra and that it can deal with a very small
quantity of sample (milligrams). FTIR experiments were
performed 40 years ago with prostatic, dental, and salivary
gland calculi.289
4.1. FTIR Spectrometry Used Routinely in the Hospital
As underlined previously, different chemical phases are present
in pathological calcifications. Spectroscopy can be used to
analyze overlapping FTIR spectra thus leading to quantitation
of numerous substances present in the calcifications.
Several CaPs more or less crystallized or carbonated can be
encountered in pathological calcifications of various origins.
Interestingly, FTIR spectroscopy is a technique allowing
identification of amorphous carbonated CaP (ACCP),
carbonated apatite (CA) and HAP (Figure 6). The different
absorption bands of apatites are well assigned. The ν1 and ν3
P−O stretching vibration modes are observed at 960−962 cm−1
and 1035−1045 cm−1, respectively, whereas the ν4 O−P−O
bending mode corresponds to the doublet at 602−563 cm−1.
The bands at 3570 and 633 cm−1 corresponding to the
stretching and vibrational modes of the OH− groups are
observed for HAP and are almost absent for the biological
apatites (CA) and ACCP. A key point in the analysis is linked
to the presence of a shoulder in the ν3 absorption band, which
can be used as a fingerprint for the presence of the ACCP
compound.290
Regarding kidney stones, most of them are made of calcium
oxalate, but CaOx monohydrate and CaOx dihydrate must be
distinguished mainly because the first is associated with
hyperoxaluria and the latter is related to hypercalciuria. Even
in difficult cases in which only one water molecule separates the
two compounds (weddelite and whewellite), CaOx identi-
fication is easy by infrared spectroscopy.
4.2. Clinical Case Characterized with Classical FTIR
Spectroscopy
From a medical viewpoint, the quantitative content of each
mineral component, as well as their spatial distribution, must be
determined for the medical report. Figure 7 shows a kidney
stone of quite large dimension (18 mm) from which the spatial
distribution of the chemical phases from the core to its surface
gives the chronological succession of the different abnormal-
ities. The core of the kidney stone is made of ammonium urate
induced by diarrhea (Figure 7B). Then, FTIR spectroscopy
reveals the presence of whewellite (Figure 7C). The associated
hyperoxaluria is due to vegetal alimentation and low diuresis.
Finally, the surface of the kidney stone is made of a mixture of
CA and weddelite related to hypercalciuria of dietetic origin
(Figure 7D).
The importance of the spatial distribution of the chemical
phases has been underlined in several examples. As reported by
Li et al.,291 the chemical composition of atheroma plaque can
be accurately revealed by FTIR spectroscopy. Several character-
istic bands can be observed: bands at 2930 and 2850 cm−1
indicate the presence of lipids, those at 1730 cm−1 the presence
of lipid esters, peaks at 1550 and 1650 cm−1 are assigned to
amide bands of proteins in fibrous tissues, and finally the broad
phosphate band at 1100−1000 cm−1 indicates the presence of
CaP-based calcification. In bone mineral,292 because phosphate
is the most abundant anion, several works293 have involved
measuring the level of mineralization, which can be estimated
by the area ratio of the ν4PO4 (500−650 cm−1) to that of amide
I band area (1600−1700 cm−1) in some cases after a medical
procedure such as ovariectomy.294
4.3. Enhancing Spatial Resolution with Synchrotron
Radiation (SR)
With a conventional blackbody source, the spatial resolution is
limited theoretically at a scale of several tens of square
micrometers. A significant breakthrough295,296 involved the
combination of a FTIR spectrometer with SR as a source297−301
and then with an optical microscope to study the distribution
and characteristics of the mineral phase in calcifications at the
micrometer spatial resolution (i.e., at the cell scale). Thus, as
reported in different review articles,302−304 the use of FTIR
spectroscopy is implemented in different SR facilities. In this
configuration, FTIR spectra with exceptionally high quality
(high signal-to-noise ratio) are collected from areas as small as
3 × 3 μm2, on as little as 10−9 g of sample.
Specific support was developed to view samples with both
FTIR and X-ray microscopes (i.e., correlate the different
organic/inorganic phases and trace metal composition in
biological cells and tissues).305
Regarding data analysis, for many medical diagnostic
problems, multivariate statistical approaches (such as principal
components analysis, linear discriminant analysis) have
replaced conventional spectroscopy analysis. Multivariate
approaches have been used to identify pathological inclusions
such as foreign matter306 and unusual soft tissue calcifica-
tions.307 In a recent review, Boskey et al.308 described the
Figure 6. Fourier transform infrared absorption spectra for the
compounds used here as references (hydroxyapatite [HAP], red;
carbonated apatite [CA], blue; amorphous carbonated calcium
phosphate [ACCP], black).
advantages of FTIR microscopy in the analysis of bone and
cartilage in healthy and diseased tissues. Regarding other kinds
of calcification, Narasimhulu et al.309 conducted a structural
study of pancreatic stones in patients with chronic pancreatitis.
XRD diagrams revealed the presence of calcium carbonate
stones, whereas the FTIR spectra reveal the presence of many
organic bands corresponding to the amide groups in proteins.
Also, calculi analysis310,311 with physical methods such as FTIR
spectroscopy or X-ray diffraction can demonstrate the presence
of the drug or its metabolites inside calculi. In calculi due to the
metabolic effects of a drug, diagnosis relies on both stone
analysis and clinical inquiry. Toscano et al.312 used FTIR
spectroscopy to measure the chemical composition of gall-
stones and found the presence of cholesterol as the main
chemical component. Also, Mattson et al. performed a chemical
analysis of articular calcium containing crystals by SR-FTIR
spectroscopy .313
Finally, by performing infrared mapping of selected areas of
the biopsy, we were able to identify at least 2 different
crystalline species in the same sample (Figure 8).314
Moreover, an optical image of a kidney biopsy shows the
glomerulus containing very refringent crystals and the proximal
Figure 7. (A) Kidney stone from a 9-year-old child. FTIR mapping of
different areas of the kidney stone: (B) ammonium urate, (C) COM,
(D) CA, and COD.
Figure 8. Optical image and mapping of an area of a kidney biopsy
(scale from blue to red with the concentration increase), and FT-IR
spectra of crystals. (a) Optical image of an area of a kidney biopsy
(BR165 specimen), (b) carbonated apatite map (done at 1030 cm−1),
(c) sodium hydrogen urate monohydrate map (done at 3600 cm−1),
and (d) FT-IR spectra of these two compounds. Reprinted with
permission from ref 314. Copyright 2007 Public Library of Science.
tubules close to the glomerulus, in which pathological deposits
were also observed (Figure 9a). The small size of the probe
allowed us to characterize separately the phases deposited in
the glomerulus and in the wall of the tubules. The crystals
agglomerated in the glomerulus were identified as sodium
foscarnet (Figure 9b). In contrast, deposits within the cells of
the proximal tubules were made of apatite (Figure 9c).
4.4. Other Major Applications of FTIR Spectroscopy in
Medical Science
Through SR-FTIR spectroscopy, at least two groups have done
outstanding work on chemical imaging. Le Naour et al.242
demonstrated from liver biopsies that bands linked to lipid
contribution such as −CH3 and −CH2, as well as esters, were
highly intense in steatotic vesicles. Moreover, a careful analysis
of the −CH2 symmetric and antisymmetric stretching modes
revealed a slight downward shift in spectra inside steatotic
vesicles as compared with spectra outside the vesicles, which
suggests a different lipid environment inside the steatotic
vesicles. Sule-́Suso et al.315−318 used both SR-FTIR and Raman
spectroscopy to assess possible differences between human
pluripotent (embryonic) and multipotent (adult mesenchymal)
stem cells and how O2 concentration in cell culture could affect
the spectral signatures of these cells. This work shows that
FTIR spectroscopy of embryonic and adult mesenchymal stem
cells have different spectral signatures based on the amount of
lipids in their cytoplasm (confirmed by cytological staining).
Furthermore, culture conditions such as O2 concentration can
affect the biochemical make up of some of these cells.
Moreover, note that several investigations regarding different
kinds of cancer have been performed recently through Raman
spectroscopies.319−326
5. WIDE- AND SMALL-ANGLE X-RAY AND NEUTRON
SCATTERING
X-ray and neutron scattering techniques have emerged as some
of the most powerful tools in materials science. The parallel
developments in materials science and neutron and SR science
worldwide have been particularly rapid. Most of our knowledge
of structure of materials has been obtained by those techniques.
Many books and several review articles are dedicated to the
fundamental aspects of these techniques.327,328 Diffraction
techniques can be used to determine the crystal structure329,330
or the chemical composition of the calcification with the
powder diffraction standards database,331 which contains more
than 64 000 patterns, including 12 000 of metals and alloys.
Here we highlight some complementary aspects with FTIR
spectroscopy. For example, diffraction techniques are quite
insensitive to unorganized organic parts of samples but give
some essential information regarding the size, morphologic
features, and orientation of the nanocrystals332,333 of the
mineral part. As noted by Sperrin et al.,334 these factors are
important when trying to elucidate the mechanism for in vivo
crystal growth. More precisely, we can estimate the crystallite
size from the broadening of the peaks by means of the Scherrer
equation (after correction for instrumental broadening with a
silicon standard) assuming negligible microstrain broaden-
ing.335 In fact, if the crystallite size broadening is generally
considered independent of the order of reflections (e.g., 001,
002, 004, etc.), the effect of microstrain depends on two theta
(2θ) and therefore on the order of reflection.336 Note that
special attention has been paid to the analysis procedure, and
several works have been dedicated to the case of
biomaterials.337
5.1. Considering Neutron and X-ray Scattering Techniques
Neutrons as a probe at the atomic scale provide another set of
nondestructive investigation techniques. Their complementar-
ity with SR may be illustrated by two physical parameters
related to the fraction of the sample analyzed and to the
amplitude of the interaction between the probe and the matter.
The first parameter is the penetration depth of the probe and
the second is the atomic diffusion factor.
Since neutrons are electrically neutral, they interact only
weakly with matter into which they can penetrate deeply. Thus,
powder neutron diffraction (PND) provides structural
information. PND thus allows for establishing an intimate
relationship between the average size of the nanocrystals of
kidney stone and its morphologic features at the macroscopic
scale. In addition, SR diffraction takes advantage of its short
penetration depth (about 20 μm for X-ray photons
corresponding to λ = 0.1 nm), as well as the small size of the
beam to establish a structural high resolution mapping of the
biological entity at the micrometer scale.
The second parameter, the atomic diffusion factor, explains
why the differences in positional parameters for heavy atoms
are marginal but can be significant for light atoms, especially for
hydrogen.338 Thus, in some cases, using neutron scattering
rather than X-ray scattering is more appropriate.339 Another
interesting application of neutron beams is inelastic neutron
scattering (INS). For example, Loong et al.340 discussed
hydroxyl-ion deficiency in apatite using INS.
Regarding the study of physiological abnormalities of bones,
we can obtain information on the orientation of the
nanocrystals, this parameter being linked to mechanical
properties. Bacon and Goodship341 showed through neutron
Figure 9. Mapping and optical image of a birefringent structure in
kidney biopsy. The poorly soluble foscarnet can be detected and
quantified after a mapping of the biopsy thanks to the characteristic
peak at 936 cm−1. Reprinted with permission from ref 314. Copyright
2007 Public Library of Science.
diffraction that the long bones of animals have the c axes of
their apatite crystals preferentially oriented to withstand
stresses.
5.2. Determining Nanocrystal Structural Parameters
For biological apatites, the crystals are nanometer-sized, with an
average length of 50 nm, 25 nm wide, and 2−5 nm thick,
scattered in the organic matrix. This nanostructure with a high
anisotropy is observed in a large number of biological apatites,
and thus an isomorph of apatite is observed whatever its
origin.342 Diffraction diagrams of different calcifications made
of carbonated apatite, cystine, whewellite and struvite are
presented in Figure 10A. The diffraction peaks of CA based
calcifications are quite broad, in line with their nanometer size,
but the other chemical phases (cystine, whewellite, struvite) are
associated with fine diffraction peaks, which reveals that the
dimension of their nanocrystals is larger. For example, in a
previous investigation, we highlighted that the dimension of
whewellite nanocrystals is about 100 nm.16
Figure 10B shows a plot of the diffraction patterns (300 K)
of the kidney stone. As noted previously, the initial background
measured on the data is high because of the significant presence
of hydrogen in biological samples. Nevertheless, the good
quality of the data allows us to proceed to a complete Rietveld-
type refinement analysis.
Therefore, we have a possible link between the dimension of
nanocrystals and the abnormality. This opportunity is
important because, as underlined previously, with pathological
calcifications, the same chemical phase can be related to several
abnormalities. An investigation of the polymorphism can be
thus the key to understanding the physicochemistry processes
associated with the disease.
5.3. Simulations of Scattering Diagram by Debye Formulas
The radial distribution method and the method of direct
intensity calculation are rather complementary to each other.343
The radial distribution method is usually preferred to analyze
scattering data, but the new generation of computers allows for
performing a complete analysis by use of the Debye formulas,
specifically with nanomaterials.344,345
Guagliardi et al. carried out a Debye function analysis of
diffraction patterns from nanosized mineral crystals of
apatite.346 The approach provides information about crystal
structure, size and shape distributions of the mineral
component of the newly formed bone.
Also, the approach is able to assess the distribution of cations
such as Zn2+ or Sr2+ in apatite, taking into account the variation
in the atomic scattering factor with energy. Similar simulations
have been performed for nanometer-scale bimetallic clusters.
5.4. Other Data/Information from X-ray and Neutron
Scattering
Diffraction techniques offer the possibility to consider
substitution processes in mineral phases found in pathological
calcifications. With apatites, two main types of substitution
exist. The first concerns the replacement of OH− or PO4
3− by
CO3
2− and the second, replacement of Ca2+ by other cations
namely, Cd2+,Pb2+, Sr2+, or Zn2+.
For example, carbonate substitution in apatites are known to
change the crystal lattice parameters depending on the type of
substitution; pure type-A substitution (CO3
2− substitutes for
OH−) causes expansion of the a- and contraction of the c-axis
parameters.347 In contrast, pure type-B substitution (CO3
2−
substitutes for PO4
3‑) causes contraction of the a- and
expansion of the c-axis dimensions.
Regarding the replacement of Ca2+ cations, through a
classical X-ray diffraction study of solid solutions
[Ca10−xCdxHAP (x = 0−10)], [Ca10−xSrxHAP (x = 0−10)],
and [Ca10−xPbxHAP(x = 0−10)], Zhu et al.348 found that the
metal ions of Pb2+, Sr2+, and Cd2+ preferentially occupied M(2)
sites in the apatite structure. Of note, in the apatite structure,
the Ca2+ ions occupy two types of nonequivalent sites:151 M(1)
is at the 4-fold site 4(f) and M(2) the 6-fold site 6(h). Clearly,
the nature of the occupation site of different metal ions in the
apatite structure may play a significant role in the adsorption
process. This result is in line with M(2) sites giving the
directional bonding of the metal ions with hydroxyl group, and
the arrangement of the staggered equilateral triangles and thus
metal ions with larger ionic radius or electronegativity
preferentially occupy the M(2) sites. Diffraction techniques
allow for investigating the interface.349 For example, with
human dentine, Bodier-Houlle ́ et al.350 gave experimental
evidence that conversion of OCP to HAP occurs during the
growing process.
Figure 10. (A) Neutron scattering diagrams of different calcifications
made of carbonated apatite (CA), cystine (Cys), whewellite (COM),
and struvite. (B) Rietveld refinement analysis, with experimental (○),
calculated () and difference powder neutron diffraction patterns of a
kidney stone sample consisting of CaOx monohydrate. Tick marks
below the profiles indicate the peak positions of allowed Bragg
reflections for the whewellite.
To study the stress distribution and orientation of apatite
crystals in bone by neutron scattering measurements,
substantial collagen must be removed to reduce the incoherent
scattering.351 Cedola et al.352 performed high-spatial-resolution
small-angle X-ray scattering (SAXS) measurements using
SR.353,354 Small-angle scattering (SAS) of X-rays (SAXS) or
neutrons (SANS) constitute powerful tools to investigate
inhomogeneities in the size range from ∼ l to 100 nm.
Regarding physiological calcifications, Zizak et al. used SAXS
to determine the size, shape, and orientation of the nanometer-
sized mineral particles at the bone/cartilage interface.355 The
authors noted the abrupt change of mineral particle orientation
at the interface between the two tissues. Using SAXS, other
authors356 considered a decalcified human femoral head section
affected by osteoarthritis (OA) and showed a slight decrease in
the axial periodicity between normal type I collagen and that in
diseased tissue in various sites. More recently, these authors
found that the established gradual reorientation of collagen
fibres from orthogonal to the surface of the joint to normal to
the bone−cartilage interface was heavily disrupted in OA.357
Also, other authors found in more advanced lesions, with loss
of cartilage, that the fibres in the calcified layer are realigned
tangential to the surface.358
The team of P. Fratzl combined SAXS scanning and
polarized FTIR spectroscopy359 to determine the molecular
orientation of apatite and collagen components. These authors
highlighted a significantly larger cancellous region than cortical
region, mineralization greater in the cortex, and crystals
oriented to a larger degree in the cancellous than cortical bone.
6. X-RAY ABSORPTION SPECTROSCOPY
SPECIFICALLY RELATED TO SR
In materials science, diffraction techniques can be completed by
structural investigation with X-ray absorption spectroscopy
(XAS),360,361 especially with nanocrystalline, amorphous solids
and biological materials.362−364 Routine use of a microbeam
(typically 15 × 15 μm) will certainly lead to new scientific
breakthroughs in medical science.365 XAS incorporates the X-
ray absorption near edge structure (XANES) and extended X-
ray absorption fine structure (EXAFS) techniques. The XANES
part refers to the near-edge part of the spectrum, whereas
EXAFS is an oscillatory structure observed over the wide
energy range of 1000 eV in X-ray absorption spectra.
6.1. XANES Spectroscopy for Characterizing Pathological
Calcifications
Recently, significant progresses were made in understanding
the XANES, the structure on the spectra within about 30 eV of
threshold.366,367 With recent developments in algorithms and
calculation speed, quantitative calculations and fits are rapidly
becoming possible in XANES, especially in the soft X-ray
region.368,369 Recently, a review on numerical simulation of soft
X-ray absorption spectra at the L edge of different elements
such as Zn has been published.370 The technique can be used to
consider the different elements inside the mineral phases itself
(i.e., the C K, P L, and Ca L edges as proposed by Benzarara et
al.371).
In a recent study,372−374 we used the XANES part of the X-
ray absorption spectra to evaluate the local environment of Ca
atoms and showed the presence of ACCP or CA compounds in
the papilla (Figure 11A).
Regarding the absorption spectra collected for reference
compounds (ACCP and CA) at the Ca K-edge (Figure
11A),375,376 the most intense transition resonance of the
spectra called the white line is observed after a prepeak α,
which can be attributed to a 1s→ 3d electron transition. Figure
11 shows that in the case of the reference CaPs analyzed
(ACCP, CA, and HAP), the prepeak is quite similar but it is not
the case for all compounds. An educational case is given with
TiO2, for which the observed pre-edge features vary both in
positions (by ∼2 ± 0.1 eV) and normalized height (from ∼0.04
to 1.0 ± 0.05) as a function of Ti coordination (4, 5, or 6
oxygen nearest neighbors).377−379
In our investigation, the white line included a shoulder-like
structure (feature β: transition 1s → 4s) and a double peak
(features γ1 and γ2: transition 1s → 4p) whose relative
intensities depend on the type of Ca crystallographic site
involved (Ca(I) or Ca(II)).
The feature α is the same between the three samples HAP,
CA and ACCP, but significant variations are measured for the
shoulder β and for the γ1−γ2 features. The XANES part is thus
sensitive to the local order around Ca2+ cations (i.e., between
the samples CA and ACCP). Of note, this type of experimental
Figure 11. (A) X-ray absorption spectra of reference compounds
(HAP, well-crystallized synthetic apatite, red; CA, biological apatite,
blue; ACCP, amorphous carbonated calcium phosphate, dotted line
black) and of different regions on the Randall’s plaque as defined in
(B). (B) Randall’s plaque at the top of the papilla and details regarding
positions (a, b, c, d) of the beam on the sample.
approach has been used for apatitic and nonapatitic CaPs of
biological interest.380
We reported without normalization the different X-ray
absorption spectra collected in moving from the top of the
renal papilla to the medulla (Figure 11B). The amplitude (la for
the spectra a) of the absorption edge (from la to ld in Figure
11A) and thus the Ca content decreases rapidly mainly because
of the presence of the calcification at the top of the papilla. The
feature α corresponds to the electronic state of calcium of 2+
being clearly visible. The positions of the features β, γ1 and γ2,
which are sensitive to the crystallinity of the calcification at the
edge, are indicated. Interestingly, the shape of feature β in
papilla 1a is close to that of feature β in ACCP. Moreover, the
two features γ1-γ2 are not present at the top of the absorption
spectra (Figure 11A, spectra a). These two observations give
direct structural evidence that one of the biochemical
mechanisms can be described as an agglomeration of ACCP
entities in the medulla leading to the formation of Randall’s
plaque at the top of the papilla.
6.2. XANES Spectroscopy for the Characterization of Trace
Elements
Trace elements can also be investigated by XAS, and results of
several studies have been published recently. Among the trace
elements that have been studied are Fe,381 Zn,382−384 Sr,385 and
Pt.386−390
Special attention has been paid to Sr, this element being part
of medical treatment for osteoporosis.391−395 Recently, Li et
al.396 showed by XAS that Sr is incorporated into mineral
crystals only in newly formed bone during Sr ranelate
treatment. Unfortunately, as underlined previously, scattering
techniques397 are sensitive to Sr content within the mineral
crystals but ignore other types of noncrystalline Sr deposits.
A first step in the localization of Sr2+ cations in bones of
patients after medical treatment can be given by knowledge of
the localization of “physiological” Sr2+ cations in pathological
calcifications. In the skeleton, the total quantity of Sr is not
insignificant, the Sr/Ca being estimated in the human skeleton
to be in the range 0.1−0.3 mg/g.398
We have thus examined a set of pathological calcifications
(Table 2) considering different structural hypothesis.
At first, Sr2+ cations are adsorbed at the surface of collagen or
apatite surrounded only by oxygen atoms (hypothesis 1 in
Figure 12A). Note that Sr2+ has variable coordination with
oxygen and water ligands, reported from 6−12, in solids and
aqueous solutions.399,400 Sr2+ cations can be engaged in the
hydrated layer at the surface of poorly crystalline apatite
nanocrystals (hypothesis 2 in Figure 12A). Finally, a
substitution occurs between Sr2+ cations and Ca2+ cations
inside apatite nanocrystals on crystallographic sites (I) or (II)
(hypothesis 3 in Figure 12A).
As performed for Zn K edge measurements, calculations by
the FEFF program can be used to localize Sr2+ cations versus
apatite nanocrystals.401
The ab initio FEFF9 code402,403 is quite useful to perform
full multiple scattering calculations in real space for nanometer
scale solids. Structural information is contained in the
modulations superimposed on the otherwise smooth atomic
absorption coefficient. The oscillatory structure can be
expressed as a sum of independent multiple scattering
contributions. Each contribution can be expressed in the
following form:
Table 2. Composition of Calcifications in Organs As
Revealed by FTIR Spectroscopy
sample
origin of the
calcification composition by FTIR spectroscopy
N 11823 kidney 66% CA, 30% ACCP, 4% protein
N 13066 kidney 79% CA, 15% ACCP, 4% protein, 2%
whewellite
N 13086 prostate 84% CA, 12% protein, 4% whewellite
N 15048 kidney 87% CA, 6% whewellite, 4% weddelite, 3%
protein
N 17161 bladder 61% CA, 30% ACCP, 8% protein, 1%
whewellite
Figure 12. (A) Schematic representation of the three structural
hypotheses regarding the localization of Sr2+ cations in bones. (B)
Details regarding the spatial repartition of atoms around Sr2+ cations
located in site (I).
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where we have separated the oscillatory and damping terms
from the mean free path and disorder. Here, n represents
different single or multiple scattering paths and Ln is the total
path length; F and θn are the amplitude and phase which
depend on the photoelectron wavenumber k, on the specifics of
the scattering path n, and on the atomic potential parameters.
For XANES spectra, these multiple-scattering path contribu-
tions, can also be summed to all orders by matrix inversion
methods, as implemented in the full multiple scattering
algorithms in FEFF9.
Here we provide different simulations to assess structural
hypotheses. For the simulation labeled Sr2+(I)-O, the local
environment of Sr2+ cations is made only by oxygen atoms
(details regarding the spatial repartition of oxygen atoms
around Sr2+ cations are given in Figure 12B) and thus
corresponds to the structural hypothesis 1. For the simulation
labeled Sr2+(I)−OP, the local environment of Sr2+ cations is
made only by O and P atoms (structural hypothesis 2, Figure
12B). For the simulations labeled Sr2+(I)−OP, Sr2+(I)−OPCa,
Sr2+(I)−OPCaP, Sr2+(I)−OPCaPO, and Sr2+(I)−OPCaPOCa,
the local environment of Sr2+ cations corresponds to structural
hypothesis 3 in Figure 12B.
For most of the numerical simulations, we observed only a
white line at the Sr K edge followed by a simple oscillation of
the absorption coefficient as we observed for experimental data
(Figure 13A). This situation does not occur with simulations
corresponding to Sr2+(I)−OPCaPO and Sr2+(I)−OPCaPOCa
for which some structures just after the white line are observed
(see arrows in Figure 13B).
These preliminary results allow for discussing the localization
of Sr2+ cations in biological apatites by XANES spectroscopy.
Because of the high disorder of the first coordination spheres of
Sr, simple adsorption of Sr2+ cations at the surface of apatite is
related to the absence of features in the XANES part of the X-
ray absorption spectra. In contrast, substituting Sr/Ca with Sr2+
cations positioned on crystallographic site (I) gives rise to
XANES features.
6.3. EXAFS Spectroscopy
EXAFS is a powerful method for local order characterization
extensively used for identifying the nature of neighboring atoms
around a selected type of atom.404 This technique can be used
to evaluate the interatomic distances, as well as structural and
thermal disorder. EXAFS gives an average description of the
local order around a selected type of atom and thus is
insensitive to polydispersity.405
The data analysis procedure is simple406,407 and is based on
the fact that a Fourier transform of EXAFS modulations can
provide a set of peaks corresponding to the different nearest-
neighbor interatomic distances. EXAFS can be used to
characterize different “objects” in biological and medical
science. As reported in the last XAFS 13th international
conference, this technique can be used to study the
environment of iron in hemoproteins,408 the imaging of
biological tissues,409 the characterization of Zn site of
nonstructural protein 3 from hepatitis C virus,410 pharmaceut-
ical compounds411 or the environment of copper in Wilson
disease.412 With dilute systems, a fluorescence detection
technique has been developed, thus opening the possibility to
consider solution samples with a concentration less than 100−
300 μM.
Regarding calcification, numerous publications described the
environment of calcium atoms even at the early beginning of
the technique, in the 1980s.413−415 For example, in the case of
bone, Harries et al.416 noted that if the nearest neighbor-
coordination to calcium is not significantly affected by the
presence of carbonate, the incorporation of carbonate into the
phosphate site alters the structural geometry beyond the
nearest-neighbor oxygen coordination to calcium consistent
with an increase in structural disorder. Hukins et al.417 used
EXAFS to characterize the phase of an amorphous calcified
deposit mixed with a crystalline phase that does not contain
calcium in encrusted urinary catheters. In such configuration,
the amorphous phase may not be detectable by X-ray
diffraction, but EXAFS reveals the presence of CaP deposited
in association with struvite.
Holt et al.418 have considered the calcium transport by the
secretory cells of the mammary epithelium: the complete set of
data including EXAFS results suggest that the caseins trap the
precipitate at the nucleation stage, effectively preventing a
potentially disastrous first-order phase transition.
Figure 13. (A) XANES spectra collected at the Sr K edge for different
pathological calcifications. (B) FEFF simulations for the environment
of Sr2+(I).
7. X-RAY FLUORESCENCE SPECTROSCOPY AND
TRACE ELEMENTS
XRF is used to determine the elemental composition of a
sample by probing the electronic structure of the atoms in the
sample, each element having electronic orbitals of characteristic
energy. Special attention must be paid to the data analysis and
specifically the absorption correction procedures for quantita-
tive analysis.419,420 In some cases total reflection XRF that is
easily qualitative for bulk analysis has to be used.
XRF has developed into a powerful tool applied to a large
variety of scientific topics and is largely implemented in
numerous SR photon factories. The use of such facilities has
decreased the detection limits (far under ppm for most
elements) and stimulated important changes in classical XRF
spectrometers.
7.1. Classical X-ray Fluorescence Spectrometry
X-ray fluorescence spectrometry technique has been used in
several studies. For example, Ekinci et al.421 investigated human
cataracts qualitatively and quantitatively by using energy
dispersive X-ray fluorescence. The standard addition method
was used for the determination of the concentration of S, Cl, K,
and Ca. A similar approach was used to determine calcium and
iodine in gall bladder stones422 and element concentrations in
blood from schizophrenic, lung cancer and leukemia
patients.423 Magalhaẽs et al. analyzed 15 breasts tissue samples
by X-ray fluorescence spectrometry to compare the elemental
concentration in healthy and carcinoma regions of the same
individual.424
7.2. X-ray Fluorescence Spectrometry on SR Facilities
Thanks to the development of optics (i.e., the use of elliptical
multilayer Bragg-Fresnel lenses), data with submicrometer
spatial resolution can be collected with X-rays425,426 and
therefore to localize the mineralization at level of the cell.427
Many studies have investigated pathological calcifications such
as gallstones, urinary stones and physiological calcifications,
such as teeth and bones.
Regarding gallstones, SR-XRF spectroscopy showed Ca and
P as the major elements, and other minor elements, such as Fe,
Cu, Zn, Se, Br, Sr, and Pb were also detected.428 Pal’chik et
al.429 identified the microelement composition of urinary
stones. They noted that apatite urinary stones contained
maximal Sr amounts, but struvite uroliths had higher Rb levels.
Also, the authors highlighted that the element composition of
urinary stones is a function of the mineral constituents,
environmental surroundings, and specific metabolism of the
patient.
Regarding physiological calcifications, Pinheiro et al.430 used
an X-ray fluorescence setup with microprobe capabilities to
evaluate the influence of life habits in dental elemental
composition. The elemental concentration values found suggest
heterogeneity of the teeth material. Moreover, the distinct
profiles for Mn, Sr, Br, and Pb were compared between teeth
from a miner and a fisherman. A link was associated between
dietary habits and environmental influence. Carvalho et al.431
found similar results: high levels of Br and Sr were associated
with environment influence and dietary habits rich in protein,
especially seafood. Also, lead is always of the order of
magnitude of the detection limit, which is 1 ± 2 μg/g in all
analyzed teeth. Abraham et al.432 investigated dental calculus
and used the atomic ratio Ca to P as an indicator of the major
crystalline structure, as well as the state of formation, of the
calculus.
Recently, Zhang et al.433 determined the elemental
concentrations in femoral heads from 5 autopsies and 7
patients with femoral neck fractures. Concentrations of P, Ca,
Fe, Cu, and Sr in the control group were higher than those in
the patient group, but concentrations of S, K, Zn, and Mn did
not significantly differ. In contrast, for diabetic osteoporosis,
bone mineral content of Ca, P, Zn, and Sr was decreased and
relative content of S increased in diabetic compared to control
femurs.434
Finally, we performed a set of X-ray fluorescence experiments
and found Zn levels greatly increased in carbonated apatite
associated with RP as compared with carbonated apatite
encountered in kidney stones, suggesting that calcified deposits
within the medullar interstitium may be a pathological process
involving a tissue reaction.435 Further studies, perhaps including
the investigation of biomarkers for inflammation, are necessary
for clarifying the role of Zn in RP formation.
7.3. Mapping at the Micrometer Scale of Pathological
Calcifications
We investigated trace elements as risk factors of RP as a logical
extension of our previous work dedicated to kidney stones. We
performed X-ray fluorescence436,437 induced by protons.
Particle-induced X-ray emission (PIXE) is a simultaneous
trace multielement analytical technique. Depending on the
proton energy and sample composition, detection limits may be
as low as pg/g. Several investigations on biological samples
have been based on PIXE experiments.438−440
More precisely, we examined the spatial distributions of Ca
and Zn in RP by PIXE. Nuclear microprobe analyses were
performed using a 2.8-MeV proton beam at the Pierre Süe
Laboratory441 and image processing using RISMIN software.442
Figure 14A represents a typical PIXE spectrum. The
contributions of the different elements, namely Ca (EKα =
3.692 KeV, EKβ = 4,013 KeV), Zn (EKα = 8.639 KeV, EKβ=
9.572 KeV), and Sr (EKα = 14.17 KeV, EKβ = 15.84 KeV) are
well-defined. Elemental maps of Ca and Zn were generated
from PIXE spectra. Each element of interest was identified by
finding the integrated photopeak area associated with its Kα
fluorescence emission. Figures 14B and C show examples of the
elemental maps of Ca and Zn obtained at 10 μm spatial
resolution.
Figures 14D and E show the cartography for Ca and Zn for
biopsy 2. For biopsy 1 (Figure 14B, C), the spatial repartition
of Ca and Zn differs greatly. Zn atoms are present at the surface
of Ca domains. The reverse configuration is observed for biopsy
2 (Figure 14D, E) for which high concentration of Zn domains
corresponds to high concentration of Ca.
At this point, we cannot describe the local environment of
Zn atoms. To obtain such information, similar experiments
have been conducted on other family of pathological
calcification through XAS experiments. From X-ray fluores-
cence spectra and thanks to the small size of the probe, SR XRF
experimental set up offers the opportunity to establish map of
different elements present in the biological sample. Recently,
different investigations have been dedicated to the character-
ization of calcifications present in damaged cartilage
tissue.443,444 Indeed, osteoarthritis (OA) constitutes a major
public health problem affecting half of the population aged over
65 years old.
In fact, different relationships exist between trace elements
and calcifications (Figure 15). From a physicochemical
viewpoint, some of these elements may induce the genesis of
such crystals445 or control their morphologic features.446 From
a medical viewpoint, Zn has antioxidant and anti-inflammatory
properties.447 Of note, BCP, or more precisely CaP apatite, is
well-known for its capacity to trap trace elements.448 Thus, the
calcification may modify the spatial distribution of Zn in the
cartilage and thus alters the associated biological function of Zn
metalloprotein.
XANES experiments begin by collecting classical X-ray
fluorescence spectra (Figure 16A), where we can distinguish
clearly the contribution of Ar present in air (experiments are
performed at atmospheric pressure), Ca, Fe, and Zn.
From these X-ray fluorescence spectra and because of the
small size of the probe (10 μm × 8 μm), mapping of the Ca (Kα
= 3691 eV) and Zn (Kα = 8638 eV) reveals that at the
mesoscopic scale, the spatial repartition of both elements is
heterogeneous (Figure 16B and C). Finally, such experiments
are performed on the DIFFABs beamline, so that X-ray
absorption spectra can be collected at the Zn K edge (Figure
16D) to obtain structural information on the Zn species
present. Note that the complete set of data has not yet been
published.
In section 5.4, we have cited works that highlighted the
structural disorder at the cartilage−bone interface with OA. In a
recent investigation, Bradley et al. noted significant modifica-
tions of the distribution maps for Ca, P, K, and S in diseased
sections at the bone−cartilage interface compared to normal
tissue.449 Similar disorders were found for Sr and Zn in samples
from equine metacarpophalangeal joints, around the tidemark
between normal and mineralized cartilage.450
7.4. Nature of the Trace Elements in Pathological
Calcifications
Recently, we aimed to classify the trace elements found in
pathological calcifications:35,266 Class 1 elements belong to the
same column of a major element of the mineral. For example,
Sr is found in CaP based calcification. Class 2 elements are Zn
or Cu, which are implied in numerous metabolic functions.
Elements such Pb, Cd, or As are the result of contamination;
they can be classified in a third class of elements. In a recent
study23 dedicated to kidney stones, we found only Pb. Of note,
a highly specific accumulation of the toxic element Pb was
recently measured in the transition zone between noncalcified
and calcified normal human articular cartilage.451 In fact, a
supplementary category including elements related to the
administration of a drug for diagnosis or therapy can be added:
among these elements are Pt452,453 and I.454
7.5. XRF at the Cellular Level
This approach has been used for nonectopic calcifications to
determine whether the abnormality induced a modification in
the content or spatial repartition of trace elements in the
calcification.455 The same approach can be used with tissues. In
that case, special attention must be paid to the effects of
radiation damage on hydrated cells.456 Palmer et al.457
described the intracellular distribution of 9 essential elements
(P, S, Cl, K, Ca, Mn, Fe, Cu, and Zn) found in cardiomyocytes
viewed by SR-X-ray induced fluorescence. Liu et al. measured
the element distribution in brain sections of rats by SR-XRF.458
Yoshida et al.459 studied the role of Fe in Parkinson’s
disease.460−462
Figure 14. (A) Typical PIXE spectra collected for a Randall’s plaque.
(B, C) Elemental maps of RP in biopsy 1: Ca (B) and Zn (C). Darker
regions indicate a higher concentration of the element (scale is 50
μm). Total collected beam charge: 0.7 μC. (D and E) Elemental maps
of RP in biopsy 2: Ca (D) and Zn (E). Darker regions indicate a
higher concentration of the element (scale is 50 μm). Total collected
beam charge: 0.4 μC.
Figure 15. Simplified representation of the interaction between
crystals, trace elements, and chondrocytes in cartilage.
8. IN VIVO STUDIES
In vivo studies are clearly the optimal experimental
configuration to observe and understand the different
physicochemical processes related to medical science. Such
experimental geometry has been used to evaluate the presence
of toxic elements in physiological calcifications.
In vivo XRF experiments463 have been performed to evaluate
the concentrations of Pb in finger bone and Cd in kidney
cortex. O’Meara et al.464 developed a technique to enhance the
XRF renal mercury detection limit. The authors noted that
despite the improved performance, detection limits remained
high as compared with typical levels in exposed individuals. A
similar approach was considered by Lee et al.,465 who combined
a K and L XRF method for the tibia bone using a system
involving109Cd point source and Ge and Si(Li) detectors for
optimum detection of the K and L X-rays, respectively.
Recently, using a similar experimental set up, Nie et al.466−468
showed that the doses delivered to the organs other than the
targeted lower leg were negligible and approval to conduct
human measurements with this system has been received from
the Research Ethics Board based on this research.
Measurements of teeth are easy and these calcifications have
been considered. Zaichick et al.469,470 showed that in the case of
tooth decay, the Sr content of enamel were 30% lower than in
healthy tooth. Also the authors highlighted that chronic
periodontitis and especially serious forms of parodontium
diseases are associated with considerable enamel demineraliza-
tion. Quantitatively, contents of Ca decreased by 30% and 20%,
respectively, on average: Sr by 50% and 53%, and Zn by 20%
and 40%. Content of Pb for every tooth study was found equal
to or lower than the detection limit, 3 μg/g.
In some cases, the detection of heavy elements leads to much
information regarding the physicochemical mechanisms. For
example, Homma−Takeda et al. showed that in proximal
tubular cells, the dominant site-specific distribution of mercury
appeared to be associated with induction of renal apoptosis and
necrosis.471
Finally, analysis of the phase composition of human kidney
stones in model objects with the use of SR diffraction was
recently published.472 Using a specific object phantom,
Ancharov et al.473 explored the phase composition of kidney
stones by X-ray diffraction using SR.
Figure 16. (A) Typical X-ray fluorescence spectrum of cartilage. We can see the contribution of Ar (Kα = 2958 eV), Ca (Kα = 3691 eV, Kβ = 4012
eV), Fe (Kα = 6404 eV, Kβ = 7058 eV), Zn (Kα = 8638 eV, Kβ = 9572 eV). (B and C) Mapping of Ca and Zn in calcified cartilage. (D) XANES
spectra at the Zn K edge.
9. OTHER APPLICATIONS OF LARGE-SCALE
INSTRUMENTS FOR ANALYZING CALCIFICATION
IN MEDICINE
Finally, the characterization of pathological calcifications by
techniques related to SR are certainly not the only medical
application.474,475 Other major opportunities exist following the
pioneers works of F. Esteve,476−482 F. Peyrin,483−489 or G.
Tromba.490,491 These teams have achieved several major
scientific breakthroughs regarding clinical mammography,
intravenous coronary angiography, or computed tomography.
Among imaging techniques, computed tomography (CT)
provides exceptionally high-quality imaging of the fine
structural detail within urinary calculi.492,493 One of the key
advantages of this approach is its combination of exceptional
details of the fine structure of human urinary stones and
chemical analysis, microCT being able to differentiate six
common mineral constituents.
Different developments combining imaging and chemical
characterization have been performed with SR facilities. For
example, X-ray transmission microtomography (CT) combined
with X-ray fluorescence microtomography (XRFCT) was
implemented in the Brazilian Synchrotron Light Laboratory
(LNLS, Campinas, Brazil).494 With this opportunity, the
concentration of some elements can be associated with
characteristics and pathology of different tissues (here breast,
prostate and lung tissues) observed by transmission CT.
10. CONCLUSIONS AND PERSPECTIVES
The societal aspect of research into pathological calcification
deserves discussion. An early diagnosis of abnormalities by
physicochemical techniques can reduce significantly the cost of
the disease treatment. For example, we recently used SR-FTIR
to identify crystals of dihydroxyadenine in a kidney biopsy from
a patient with a homozygous adenine phosphoribosyltransferase
deficiency, for which no diagnosis was available to explain fast
progressing renal failure.495 Specific treatment resulted in
improved kidney function. In such an abnormality, the absence
of an accurate diagnosis and specific treatment would lead to
end-stage renal failure. From an epidemiological point of view,
this disease is not diagnosed throughout the world. In France,
we have observed more than 60 cases, and in other countries
(except Japan), about 100 cases have been identified. The same
pattern is observed for primary hyperoxaluria type 1, another
genetic disease leading to end-stage renal failure. The diagnosis
is based on stone morphologic features and crystal structural
organization, as shown in Figure 2C. Unfortunately, few
laboratories offer the opportunity to take into account stone
morphologic features in addition to stone composition. As a
consequence, often stones formed because of this disease are
considered related to dietary disorders rather than having a
genetic origin, and often the diagnosis is made after the total
loss of kidney function.
From an economic point of view, the annual cost of dialysis
per patient in France is about 50 000 €, and the cost of kidney
replacement is also 50 000 €, with the risk of recurrence of the
disease on the graft transplant without diagnosis. This cost may
be compared with the annual cost of drug treatment, less than
40€, which is very effective. Of note, the cost of measurement
using SR-FTIR is about 1000€.
This example could be applied to a number of pathologies,
including genetic diseases, cancer, and diseases related to
environmental factors and diagnosed late. Regarding medical
applications, we moved from the use of very few hours on
selected SR beamlines496−504 to SR facilities fully dedicated to
such applications.505
Moreover, with the arrival of new generations of SR facilities
(e.g., SOLEIL, Diamond, ALBA in Europe) as well as major
improvements in other SR facilities in Brazil, China, Japan or
South Korea, many of the above type of research topics could
be extended. Indeed, the first application of SOLEIL was
dedicated to the study of kidney stones.506
Right now, an SR factory can be used to perform a medical
diagnosis, which is relevant in terms of rapidity and efficiency
versus other techniques present in the hospital. Recently, we
saved the kidney function of one patient and realized a
diagnosis for more than 20 others. Similar applications were
achieved with other characterizations or imaging techniques in
SR facilities.
The massive gains in knowledge coupled with the fact that
we can now consider different techniques for in vivo
experiments means many bright prospects for investigations
of pathological calcifications using large-scale instruments
around the world.
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Dr. R. Weil (LPS). This work was supported by the Physics and
Chemistry Institutes of CNRS and by contract ANR-09-BLAN-
0120-02. The authors are grateful to the Soleil SR Facility and
the Leon Brillouin laboratory for beam time allocation.
REFERENCES
(1) Biomineralisation: Chemical and Biochemical Perspectives; Mann, S.,
Webb, J., Williams, R. J. P., Ed.; VCH Verlag: Weinheim, Germany,
1990.
(2) Lindroos, M.; Kupari, M.; Heikkila, J.; Tilvis, R. J. Am. Coll.
Cardiol. 1993, 21, 1220.
(3) Nouvelles met́hodes d’et́ude des calculs et plaques de Randall. In
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Veŕon, E.; Matzen, G. J. Appl. Crystallogr. 2009, 42, 109.
(26) Daudon, M.; Jungers, P.; Bazin, D. New Engl. J. Med. 2008, 359,
100.
(27) Van Meerssche, M. ; Feneau-Dupont, J. Introduction a ̀ la
Cristallographie et a ̀ la Chimie Structurale; Vander: Louvain-Cesson,
Belgium, 1973.
(28) Schoppet, M.; Al-Fakhri, N.; Franke, F. E.; Katz, N.; Barth, P. J.;
Maisch, B.; Preissner, K. T.; Hofbauer, L. T. J. Clin. Endocrinol. Metab.
2004, 89, 4104.
(29) Cazalbou, S.; Eichert, D.; Drouet, C.; Combes, C.; Rey, C. C. R.
Palevol. 2004, 3, 563.
(30) Wang, L.; Guan, X.; Du, C.; Moradian-Oldak, J.; Nancollas, G.
H. J. Phys. Chem. C. 2007, 111, 6398.
(31) Seeman, N. C.; Belcher, A. M. Proc. Natl. Acad. Sci. U.S.A. 2002,
99, 6452.
(32) Zamiri, A.; De, S. J. Mech. Behav. Biomed. Mat. 2011, 4, 146.
(33) Paine, M. L.; Snead, M. L. J. Bone Miner. Res 1996, 12, 221.
(34) Ryall, R. L. World J. Urol. 1997, 15, 155.
(35) Bazin, D.; Chevallier, P .; Matzen, G.; Jungers, P.; Daudon, M.
Urol. Res. 2007, 35, 179.
(36) Slojewski, M.; Czerny, B.; Safranow, K.; Jakubowska, K.;
Olszewska, M.; Pawlik, A.; Golab, A.; Drozdzik, M.; Chlubek, D.;
Sikorski, A. Biol. Trace Elem. Res. 2010, 137, 301.
(37) Gomes, S.; Nedelec, J. M.; Jallot, E.; Sheptyakov, D.; Renaudin,
G. Chem. Rev. 2011, 23, 3072.
(38) Durak, I.; Kilic, Z.; Sahin, A.; Akpoyraz, M. Urol. Res. 1992, 20,
23.
(39) Perk, H; Ahmet Serel, T.; Kosar, A.; Deniz, N.; Sayin, A. Urol.
Int. 2002, 68, 286.
(40) Garban, Z.; Avacovici, A. E.; Garban, G.; Peter, F.; Ghibu, G. D.;
Botoca, M.; Cumpanas, A. Stud. Univ. Babes-Bolyai, Chem. 2010, 55,
103.
(41) Slojewski, M.; Czerny, B.; Safranow, K.; Drozdzik, M.; Pawlik,
A.; Jakubowska, K.; Olszewska, M .; Golab, A.; Byra, E.; Chlubek, D.;
Sikorski, A. Urol. Res. 2009, 37, 317.
(42) Grases, F.; Genestar, C.; Mill, A. J. Cryst. Growth 1989, 94, 507.
(43) Ozgurtas, T.; Yakut, G.; Gulec, M.; Serdar, M.; Kutluay, T. Urol
Int 2004, 72, 233.
(44) Touryan, L. A.; Lochhead, M. J.; Marquardt, B. J.; Vogel, V. Nat.
Mater. 2004, 3, 239.
(45) Durak, I.; Kilic, Z.; Perk, H.; Sahin, A.; Yurtarslani, Y.; Yasar, A.;
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(151) Bolleé, G.; Dollinger, C.; Boutaud, L.; Guillemot, D.;
Bensman., A.; Harambat, J.; Deteix, P.; Daudon, M.; Knebelmann,
K.; Ceballos-Picot, I. J. Am. Soc. Nephrol. 2010, 21, 679.
(152) Giachelli, C. M. J. Am. Soc. Nephrol. 2003, 14, S300.
(153) Sun, Y.; Zeng, X. R.; Wenger, L.; Cheung, H. S. Biochem.
Biophys. Res. Commun. 2003, 312.
(154) Hsu, H. H. T.; Abbo, B. G. Biochim. Biophys. Acta, Mol. Basis
Dis. 2004, 1690, 118.
(155) Steitz, S. A.; Speer, M. Y.; McKee, M. D.; Liaw, L.; Almeida,
M.; Yang, H.; Giachelli, C. M. Am. J. Pathol. 2002, 161, 2035.
(156) Vogel, P. M.; Georgiade, N. G.; Fetter, B. F.; Vogel, F. S.;
McCarty, K. S. Am. J. Pathol. 1981, 104, 23.
(157) Guinebretier̀e, J. M.; Menet, E.; Tardivon, A.; Cherel, P.;
Vanel, D. Eur. J. Radiol. 2005, 54.
(158) Klimas, R.; Bennett, B.; Gardner, W. A., Jr. Prostate 2006, 7, 91.
(159) Moskowitz, M. A.; Winickoff, R. N.; Heinz, E. R. N. Engl. J.
Med. 1971, 285, 72.
(160) Harrington, M. G.; Macpherson, P.; McIntosh, W. B.; Allam, B.
F.; Bone, I. J. Neurol., Neurosurg. Psychiatry 1981, 44, 1168.
(161) Li, J. J.; Zhu, C. G.; Yu, B.; Liu, Y. X.; Yu, M. Y. Aging Res. Rev.
2007, 6, 263.
(162) Woods, J. E.; Soh, S.; Wheeler, T. M. Arch. Pathol. Lab. Med.
1998, 122, 152.
(163) Bach, A. M.; Hann, L. E.; Hadar, O.; Shi, W.; Yoo, H. H.;
Giess, C. S.; Sheinfeld, J.; Thaler, H. Radiology 2001, 220, 70.
(164) Gahl, W. A.; Thoene, J. G.; Schneider, J. A. N. Engl. J. Med.
2002, 347, 111.
(165) Kajander, E. O.; Ciftci̧oglu, N. Proc. Natl. Acad. Sci. U.S.A.
1998, 95, 8274.
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